Managed care (Langhorne, Pa.) · 2013
Molecular monitoring of response in patients with chronic myeloid leukemia.
СтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kolibaba Kathryn S
Аннотация
PURPOSE: To discuss the importance of regular, consistent use of molecular testing to monitor treatment response and minimal residual disease in patients with chronic myeloid leukemia (CML), as recommended in established practice guidelines.
DESIGN: This review outlines the efficacy of BCR-ABL1 tyrosine kinase inhibitors (TKIs) in eliciting significant treatment responses in patients with CML; describes the positive effect of achieving molecular responses on long-term outcomes; discusses the importance of regular, consistent molecular monitoring in CML; and highlights issues critical to the implementation of molecular monitoring in routine practice.
METHODS: Published literature pertaining to molecular monitoring of the response to BCR-ABL1 TKI therapy for CML was searched and reviewed.
RESULTS: BCR-ABL1 TKI therapy for CML can reduce the disease burden to a level detectable only by molecular methods. Although practice guidelines recognize the importance of molecular monitoring of disease
DESIGN: This review outlines the efficacy of BCR-ABL1 tyrosine kinase inhibitors (TKIs) in eliciting significant treatment responses in patients with CML; describes the positive effect of achieving molecular responses on long-term outcomes; discusses the importance of regular, consistent molecular monitoring in CML; and highlights issues critical to the implementation of molecular monitoring in routine practice.
METHODS: Published literature pertaining to molecular monitoring of the response to BCR-ABL1 TKI therapy for CML was searched and reviewed.
RESULTS: BCR-ABL1 TKI therapy for CML can reduce the disease burden to a level detectable only by molecular methods. Although practice guidelines recognize the importance of molecular monitoring of disease